BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 33275673)

  • 21. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
    Zoi K; Cross NC
    Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.
    Hochman MJ; Savani BN; Jain T
    EJHaem; 2021 Aug; 2(3):607-615. PubMed ID: 35844680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapeutic targets for chronic myelomonocytic leukemia.
    Lasho T; Patnaik MM
    Best Pract Res Clin Haematol; 2021 Mar; 34(1):101244. PubMed ID: 33762099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
    Patnaik MM; Tefferi A
    Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
    Lasho T; Patnaik MM
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
    Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
    Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2022 Mar; 97(3):352-372. PubMed ID: 34985762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.
    Fontana D; Elli EM; Pagni F; Piazza R
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
    Wan Z; Han B
    Front Oncol; 2020; 10():579221. PubMed ID: 33117717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
    Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
    Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
    Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
    Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
    Szuber N; Orazi A; Tefferi A
    Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
    Triguero A; Xicoy B; Zamora L; Jiménez MJ; García O; Calabuig M; Díaz-Beyá M; Arzuaga J; Ramos F; Medina A; Bernal T; Talarn C; Coll R; Collado R; Chen TH; Borrás J; Brunet S; Marchante I; Marco V; López-Cadenas F; Calbacho M; Simiele A; Cortés M; Cedena MT; Pedreño M; Aguilar C; Pedró C; Fernández M; Stoica C; Ribera JM; Sanz G
    Leuk Res; 2022 May; 116():106836. PubMed ID: 35405632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression in Myeloid Neoplasms: Beyond the Myeloblast.
    Faria C; Tzankov A
    Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2020 Jan; 95(1):97-115. PubMed ID: 31736132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.
    Kanagal-Shamanna R; Orazi A; Hasserjian RP; Arber DA; Reichard K; Hsi ED; Bagg A; Rogers HJ; Geyer J; Darbaniyan F; Do KA; Devins KM; Pozdnyakova O; George TI; Cin PD; Greipp PT; Routbort MJ; Patel K; Garcia-Manero G; Verstovsek S; Medeiros LJ; Wang SA; Bueso-Ramos C
    Mod Pathol; 2022 Apr; 35(4):470-479. PubMed ID: 34775472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.